The Hong Kong Securities Regulatory Bureau worry about the wishes of the holding，Kelun Pharmaceutical (002422.SZ) finally announced on the evening of October 31st on October 31st。The previous acquisition has been postponed twice。
 
Long -term tracking of Kellen Pharmaceutical Medical Private Equity Tell the Weekly Reporter: & ldquo; This is the acquisition from a strategic level，Lijun and Keron in the product structure、The area distribution is all collaborative，Although I can't see the improvement of the report in the short term，But we are very optimistic，Unfortunately, the acquisition failed。& rdquo;
 
Affected by restricted resistance，Kelun Pharmaceutical has difficulty maintaining the performance growth rate before listing，The stock price once fell into a downturn。
 
However, some people think that the large infusion has gone through the industry's lowest point。& ldquo; Keron is in the next jump to squat before the new level。& rdquo;
 
The market focuses on Stake Sports Bettingthe stake sports betting appantibiotic intermediate project invested by 4.8 billion in Xinjiang。Researchers from the buyer's institution made a metaphor for it & mdash; & mdash; & ldquo; sharks & rdquo;。According to Kellen Pharmaceutical's previous calculation，This project will be re -created after delivery。
 
Two postponed extension to terminate the acquisition
 
October 31 evening，Keron Pharmaceutical announced & ldquo; Termid the acquisition of some equity projects & rdquo;，Calculating & ldquo; I still failed to obtain opinions from relevant overseas departments，At the same time, the prerequisites agreed in the shares' sale agreement after two extension of the parties have not achieved & rdquo;，and said & ldquo; In the next six months, the company will no longer discuss any form of the acquisition of some equity projects of Lijun International、Planning and other matters & rdquo;。
 
Everything is sudden。But the market seems to have awareness，On October 31st, the stock price of Kellen Pharmaceutical fell 1.22 yuan，Fall 2.65%.
 
December 28 last year，Kelly Pharmaceutical and Lijun International shareholders Junlian Industrial and China Pharmaceuticals signed the "Shares Sale Agreement"，It is agreed that it will acquire its respective 180 million shares of Lijun International at a price of 525 million Hong Kong dollars (equivalent to RMB 426 million), respectively.。After the equity is transferred, Kellen Pharmaceutical will hold 360 million shares of Junjun International，A total of 12.287%equity。
 
Now in the field of infusion，Keron Pharmaceutical is recognized as No. 1 leader (2012 data: sales of about 3.8 billion bottles，accounting for about 40%of the market share)，Followed by Lijun International and China Resources Double Crane，stake sports betting appMy stake betting appThree markets with a total of 50%melon。
 
Organists who have followed up for a long time to follow up with Kelly Pharmaceut，& ldquo; This is a strategic collaboration。Lijun International has two main business，First is the big infusion of the four medicines of Shijiazhuang，Second is the antibiotics of Xi'an Lijun。Softbags of Shijiazhuang Four Medicine，The most important products of Keron can make a bag，Do not overlap on the product line，And the main competitors of Keron, Shuanghe, just make a soft bag，This can balance the opponent。This is the collaboration on the product line。There is a little bit，Shijiazhuang Four Medicine Headquarters in Hebei，It is in Hebei、Tianjin、Beijing is well sold in that area。and Colom sells well in the south。It can’t enter the north because Shuanghe is also very strong。Shijiazhuang Four Medicine has always had a foundation in that area，Equivalent to directly insert the hinterland of Shuanghe，So the two people's synergy in the region is very strong。& rdquo;
 
Approve the approval of the Development and Reform Commission will follow on May 6, 2013。All domestic approval procedures are also completed at the end of July。When you see this acquisition, you need to push up quickly。
 
Dan Kelun Pharmaceuticals extended twice，The latest time of the agreed prerequisites was reached by & ldquo; June 30, 2013 & rdquo; delayed to & ldquo; August 31, 2013 & rdquo;，Then push back to & ldquo; October 31 & rdquo;。
 
In the transaction announcement，Keron Pharmaceutical clearly expressed the subsequent intention to increase its holdings: & ldquo; After the agreement of the agreement was completed，In the open market and other legal methods, the shares of Lijun International were purchased from the public market and other Stake Sports Bettingstake online sports bettinglegitimate methods with a total of no more than 2.463 billion yuan (equivalent to RMB 2 billion).
 
Sources disclosed，& ldquo; The SEC (Hong Kong Securities Regulatory Commission) realized that Colom's willingness to continue to increase its holdings to the largest shareholder is very obvious，Therefore, is it consistent with the other two shareholders of Keron and other two shareholders.，Only caused the approval progress to delay。& rdquo;
 
Specific details cannot be known.
 
As the final period approaches，Recently, there have been new news in the market，Calculating & ldquo; Because the requirements must be reached before October 31, the requirements of the SEC must meet the requirements of the prerequisites，This equity transaction will continue to extend until November。Can you succeed in the final level，Suspense。& rdquo;
 
Some investors ask for verification on the panoramic network interactive platform，Dan Kelun Pharmaceutical only indicates，& ldquo; The project is being reviewed by the Hong Kong Securities Regulatory Commission，We are currently waiting for its reply。If there is a substantial progress，The company will strictly follow the information disclosure rules，Give it complete、Discover in time。& rdquo; until the morning of October 31，Reporter calls Kellen Pharmaceutical Securities Department，Its staff still insists on expressing，& ldquo; We are waiting for the reply from the Hong Kong Securities Regulatory Bureau。& rdquo;
 
less than half a day after a while，The story of the giant who told the giant for nearly a year suddenly stopped abruptly。
 
& ldquo; In our opinion，It was not particularly concerned about the progress of its specific asset reorganization or acquisition，We mainly look at its strategy，It does not say how much performance can My stake betting appstake sports betting appbe thickened or how much profit can be improved，But it is strategically good，Can check the opponent。& rdquo; Guangzhou private equity is surprised and regrettable，& ldquo; I didn’t expect it to be able to do it。& rdquo;
 
November 1，Kellen Pharmaceutical's stock price continues to fall 0.51%.